In several studies, anti-PD1 was combined with chemotherapy (amrubicin, paclitaxel, gemcitabine, and liposomal formulation [LF]-eribulin) in pretreated patients with SCLC but with limited benefit, as reported in Table S9 [139,140,141,142]. This evidence concerns the gene PDCD1 and small cell lung carcinoma.